Carlos Milla is Professor of Pediatrics and (by courtesy) of Medicine at Stanford University School of Medicine, where he is Associate Director for Translational Research at the Center for Excellence in Pulmonary Biology at Stanford. Dr Milla is also the Director of the Stanford Cystic Fibrosis (CF) Center, the Stanford Primary Ciliary Dyskinesia (PCD) Center, and the Stanford CF Translational Therapeutics Development research program.
He has actively participated in multiple clinical translational research studies and has accumulated substantial expertise on the pathophysiology, diagnosis and development of novel outcomes for pediatric pulmonary disorders.
In addition, Dr Milla has long-standing expertise in drug development through a large number of clinical trials, from early phase to pivotal trials, as well as participating in multiple advisory boards for drug development focused on CF, PCD and other airway disorders. This includes holding several patents and being corporate board member of startup biotech companies with a focus on pulmonary disorders.
Dr Milla has published and lectured extensively on the topics of CF and PCD, and the genetics of rare lung diseases. Current areas of research include early lung disease development and the pathophysiologic mechanisms involved in the defective mucociliary clearance characteristic of CF, PCD and bronchiectasis. Additional research interests include active programs for remote monitoring and biomarker discovery for chronic pulmonary conditions.
